Stapokibart shows nasal symptom reduction in pediatric seasonal allergic rhinitis case series

A retrospective case series evaluated stapokibart in 20 patients under 18 years old with moderate-to-severe seasonal allergic rhinitis. The intervention was stapokibart treatment, starting with a 600 mg dose followed by a 300 mg maintenance dose after 2 weeks, compared to baseline. The primary outcome was change in visual analog scale (VAS) scores for nasal symptoms after 1 month.

All 20 patients (20/20) demonstrated significant reductions in nasal VAS scores compared with baseline after 1 month of treatment, with a reported P value of <0.05. The specific effect size was not reported. Secondary outcomes included symptom control during the allergic season and drug safety, but results for these were not detailed.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. Key limitations include the retrospective design, the case series methodology which lacks a control group, and the small sample size of 20 patients. The funding source and conflicts of interest were not reported.

Given the uncontrolled, observational nature of this evidence, the findings should be interpreted as preliminary. They suggest a signal of efficacy for stapokibart in reducing nasal symptoms in this pediatric population, but do not establish causality or comparative effectiveness. Controlled trials are needed to confirm these observations and fully assess the benefit-risk profile.